clinical research prime

Pediatric Phlebotomist

Intranasal RSV

  • 24-59 months of age.
  • A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine in RSV Seropositive Children.
  • Participants will receive study related treatment at no cost and will be compensated for time and travel.

Senior RSV 60+

  • A Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Adults 60 Years of Age or Older. 
  • Participants will receive study related treatment at no cost and will be compensated for time and travel.